BioWorld

Jan. 24, 2002

View Archived Issues

EntreMed, Allergan Collaborate On Ophthalmic Uses Of Panzem

Allergan Inc. struck a five-year deal potentially worth more than $40 million with EntreMed Inc. to develop and commercialize the latter’s angiogenic inhibitor, Panzem, for ophthalmolic uses. Read More

Xenerex Enters Antibody Deal With Schering-Plough’s DNAX

Read More

3-D Structure Of Deadly Bacillus Anthracis Edema Factor Protein Reveals Drug-Finding Weak Spot

Read More

NeurogesX Raises $23M To Develop Products For Pain

Read More

Other News To Note

Read More

U.S. Patent Disclosures

Read More